Medarex, Lonza Sign Collaboration Agreement

Published: 09-Jul-2009

Medarex to provide manufacturing services in support of the development and commercialization of its pipeline of therapeutic proteins and ADCs

Lonza and Medarex have signed an agreement. According to the agreement, Medarex would provide manufacturing services in support of the development and commercialization of Medarex’s pipeline of therapeutic proteins and antibody drug conjugates (ADCs).

This collaboration represents the continued extension of Lonza’s contract manufacturing business model.

The Medarex agreement leverages Lonza’s expertise and asset base in biologics manufacturing and its new facilities, to produce antibody drug conjugates in milligram to multiple kilogram quantities for both clinical and commercial supply.

Stephan Kutzer, Head of Lonza, said: “We are pleased to be working with such a successful mid-size biotech company to advance and strengthen their robust portfolio of innovative therapies. Supporting Medarex’s immediate and long-term needs with our expertise in mammalian cell culture and antibody drug conjugates is both exciting and rewarding.”

No items to display

Tell your friend about this article